GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Float Percentage Of Total Shares Outstanding

Immutep (ASX:IMM) Float Percentage Of Total Shares Outstanding : 67.04% (As of May. 01, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Immutep Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immutep's float shares is 796.97 Mil. Immutep's total shares outstanding is 1,188.83 Mil. Immutep's float percentage of total shares outstanding is 67.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immutep's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immutep's Institutional Ownership is 17.26%.

Immutep Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Immutep's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=796.97/1,188.83
=67.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep (ASX:IMM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ASX:OPT ASX:PYC ASX:IMU ASX:BOT ASX:CUV ASX:CU6 ASX:RAC ASX:DXB ASX:PIQ ASX:RCE OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
PRRUF:USA IMMP:USA YP1B:Germany
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Website
https://www.immutep.com
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines